Investor Relations
NASDAQ Capital Market
KTTA
Corporate Profile
Pasithea Therapeutics (NasdaqCM: KTTA) is a clinical-stage biotech focused on the discovery, research, and development of innovative treatments for RASopathies, MAPK pathway-driven tumors, and other diseases, including central nervous system (CNS) disorders.
Latest Financials
Latest Press Releases
Email Alerts
Sign up for our investor alerts to get earnings updates, press releases, and corporate news delivered straight to your inbox.